Cosmetic Dermatology & MediSpa of NJ Sees Surge in BodyTite Treatments as GLP-1 Medication Usage Spurs Demand for Skin Tightening Solutions
WAYNE, N.J., May 12, 2025 /PRNewswire/ — Cosmetic Dermatology & MediSpa of NJ, a leading cosmetic dermatology center in New Jersey (with locations in Englewood, Wayne, and Newark), proudly announces a notable increase in demand for BodyTite, a revolutionary minimally invasive body contouring procedure that uses radiofrequency (RF) energy to melt fat and tighten skin. The surge is being largely attributed to the growing number of patients using GLP-1 agonists—popular medications prescribed for weight loss, including semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®).
While GLP-1 medications have delivered transformative weight-loss results for thousands, many patients are now confronting an unintended cosmetic concern: loose, sagging skin—especially around the arms, abdomen, thighs, and neck.
'We're seeing an unprecedented number of post-weight-loss patients who are thrilled with their health gains but now want to optimize their appearance,' said Dr. Chang B. Son 'BodyTite is a game-changer for these individuals. It offers significant skin tightening and body contouring results without the downtime and scarring associated with traditional plastic surgery.'
Why BodyTite?
BodyTite utilizes advanced RF-assisted lipolysis to:
Melt stubborn fat pockets
Stimulate collagen production
Tighten lax skin
Deliver surgical-like results without scalpels or sutures
Patients experience shorter recovery times, reduced bruising, and visible results within weeks—with continued improvements over several months.
As GLP-1-based therapies continue to gain popularity for both medical and lifestyle-driven weight loss, Cosmetic Dermatology & MediSpa of NJ has proactively adapted to meet patient needs. BodyTite now serves as a gold standard treatment for those who wish to complete their transformation with firmer, sculpted skin.
Cosmetic Dermatology & Medispa of NJ (Wayne, Englewood, & Newark) are premier med spas and anti-aging practices providing the most contemporary treatments to help you look and feel your best!
Cosmetic Dermatology & Medispa of NJ1777 Hamburg TurnpikeSuite 302-D, Wayne, NJ 07470(973) 382-9391
https://www.cosmeticdermatologymedispanj.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Arbonne Unveils Innovative Plant-Powered Hair Care Collection Fueled by Scalp Science and Clinical Results
IRVINE, Calif., June 13, 2025 /PRNewswire/ — Arbonne, a global leader in plant-powered personal care, has officially launched its new Hair Care Collection, a comprehensive system designed with scalp health and hair vitality in mind. Revealed at the company's Global Training Conference on June 12, 2025, in Las Vegas, the five-product line reflects Arbonne's commitment to ingredient integrity, formulation transparency, and science-backed innovation. The collection includes: Restorative Shampoo Replenishing Conditioner Scalp Elixir Nourishing Hair Oil Bond Building Mask Powered by purposeful, performance-driven ingredients—like Green Coffee Oil, Pea Peptide, Snow Mushroom, Argan, Avocado, and Squalane—each product is designed to support scalp and hair health while delivering visible results. All formulas are dermatologist-tested, vegan, cruelty-free, and crafted without over 2,000 ingredients Arbonne chooses not to include in its product development process. 'This collection reflects a forward-thinking approach to hair wellness,' said Lori Burgher, Chief Marketing Officer at Arbonne. 'By focusing on the health of the scalp, supported by carefully selected botanical and science-based ingredients, we're helping people achieve stronger, more resilient hair over time.' Scalp Elixir: A Targeted Approach to Scalp Wellness At the forefront of the collection is the Scalp Elixir, a targeted scalp treatment designed to support scalp homeostasis and help reduce visible buildup. Its advanced formulation reflects Arbonne's approach to creating purposeful products that are both effective and grounded in scientific study. Scalp Elixir Performance Highlights After 4 Weeks: 96% of participants reported improvement in scalp buildup* 58% average visible reduction in scalp buildup based on clinical grading** 60% average visible improvement in the appearance of the scalp surface** 16% average visible improvement in hair density and volume*** 85% of users observed visible results within 4 weeks *Based on perception results of 33 participants using 1–2 droppers of HairCare Scalp Elixir across the scalp twice daily for 4 weeks.**Average based on clinical grading of 31 participants using 1–2 droppers across the scalp twice daily for 4 weeks.***Average based on clinical grading of 28 participants using 1–2 droppers across the scalp twice daily for 4 weeks. This performance data underscores Arbonne's investment in formulas that are rigorously tested, intentionally developed, and designed to support overall scalp wellness and healthier-looking hair. Rooted in Science. Guided by Standards. Arbonne's HairCare Collection is now available through Arbonne Independent Consultants and at Each product reflects Arbonne's guiding principles: using plant-powered ingredients, prioritizing ingredient transparency, and delivering real performance validated through testing. About ArbonneArbonne is a B Corporation® Certified global health and wellness company that believes in a holistic approach to beauty, health, and wellbeing. Since 1980, Arbonne has combined the best of nature and science to create high-performing products backed by rigorous standards and a passionate community.
Malaysian Reserve
6 hours ago
- Malaysian Reserve
CureLab Veterinary's ElenaVet™ Gene Therapy Delivers 90% Success in Pet-Dog Osteoarthritis Study
Frontiers in Veterinary Science paper reports rapid, significant pain relief with weekly p62-plasmid injections and no significant side-effects BOSTON, June 13, 2025 /PRNewswire/ — CureLab Veterinary Inc., a pioneer in developing innovative veterinary therapeutics to combat cancer and inflammatory diseases in pets, announced publication of a peer-reviewed pilot study demonstrating that ElenaVet™, the company's investigational p62-plasmid gene therapy, markedly reduced chronic osteoarthritis (OA) pain in companion dogs while exhibiting an excellent safety profile. The article, titled 'Efficacy of p62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study,' appears in Frontiers in Veterinary Science (DOI 10.3389/fvets.2025.1519881). Key findings 17 client-owned dogs with radiographically confirmed OA received 1 mg intramuscular ElenaVet™ once a week for 10 weeks. Pain Severity Score (PSS) fell from 5.25 → 3.25 and Pain Interference Score (PIS) from 7.0 → 3.27 on the Canine Brief Pain Inventory (CBPI). 90% of dogs met the study's pre-defined 'treatment success' criteria (≥1-point PSS drop and ≥2-point PIS drop). Quality-of-life ratings of 'good/excellent' rose from 1 to 12 dogs. First owner-noticed improvements occurred within 2–4 weeks; scores plateaued by week 6. No significant adverse events—no vomiting, diarrhea, seizures, or lab abnormalities—were reported during treatment. Executive & scientific commentary'ElenaVet™ has now shown—in a rigorous, peer-reviewed setting—that a weekly gene-based therapy can deliver meaningful, durable pain relief without the organ-toxicity risks of long-term NSAID use,' said Robert Devlin, general manager of CureLab Veterinary. 'These results put us on a clear path toward larger, controlled trials and eventual U.S. approval.' 'The p62 plasmid dampens multiple inflammatory pathways simultaneously,' added Vladimir Gabai, PhD, chief science officer and lead author of the study. 'Because we encode p62 in a simple plasmid, we can administer a low-dose injection that teaches muscle cells to make the dog's own anti-inflammatory agent—no complex biologic manufacturing or cold chain required.' Addressing a widespread unmet needOsteoarthritis affects an estimated one in five adult dogs; chronic use of standard NSAIDs can raise blood pressure, cause gastric ulcers and, in some cases, damage kidneys or liver. ElenaVet™ aims to offer a safer, compliance-friendly alternative—potentially as monthly or 'as-needed' injections, once dose-frequency optimization studies are complete. Next stepsCureLab Veterinary has initiated discussions with the USDA Center for Veterinary Biologics (CVB) to finalize pivotal study protocols assessing dose range, durability of effect and long-term safety. With adequate funding, the company anticipates submitting a licensing application within 2–3 years. About ElenaVet™ElenaVet™ is a circular DNA plasmid encoding the SQSTM1/p62 protein, delivered via intramuscular injection. The therapy is designed to up-regulate the body's own anti-inflammatory mediators, providing multimodal relief from chronic inflammatory conditions such as osteoarthritis. About CureLab Veterinary Veterinary Inc. is a pioneering biopharmaceutical company dedicated to developing innovative cancer treatments for pets. The company's mission is to help pets live longer, healthier, and happier lives by providing them with access to the most advanced therapies available. CureLab Veterinary is committed to advancing the field of veterinary oncology through research, development, and collaboration with leading academic institutions and industry partners. The company's intellectual property portfolio, developed over the last decade, includes patents granted in more than 25 countries. To learn more, visit Investigational status / safe-harbor statementElenaVet™ is an investigational therapy not yet approved for commercial use; safety and efficacy have not been established by U.S. regulatory authorities. This press release contains forward-looking statements subject to risks and uncertainties. Media contactTim Cox | ZingPR for CureLab Veterinary | tim@
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
ARLINGTON, Va., June 13, 2025 /PRNewswire/ — Kalorama Information, a leading publisher of life sciences market research, has released the highly anticipated third edition of its landmark report, Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025. This comprehensive analysis offers an in-depth look at the financial ecosystem fueling the explosive growth of the cell and gene therapy (CGT) industry — a market defined by breakthrough innovation, global competition, and evolving funding landscapes. The report is released in two installments, with the first part available now, covering deals through Q4 2024. The second installment, included with purchase, will be released in Fall 2025 and cover activity through Q3 2025. 'Many categories of deals, such as collaborations, distribution/co-marketing, and manufacturing/supply chain, have shown a long-term pattern of growth,' said Justin Saeks, senior market analyst at Kalorama Information. 'And there's reason for optimism regarding continued investments. Cell and gene therapy-related companies have continued to receive huge amounts of investment.' Key Insights from the Report: Over 2,000 CGT-related deals analyzed, with quarterly trends tracked from Q1 2021 to Q4 2024 Despite a tighter funding environment, 2024 investment reached an estimated $39 billion, with a sharp Q4 uptick Top dealmakers include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly Deal types covered: VC/PE, IPO/SPAC, licensing, tech transfer, acquisitions, supply chain partnerships, and more Global perspective includes detailed breakdowns by region — North America, Europe, and APAC Why This Matters Now The CGT market is maturing fast, with fluctuating investment trends, growing deal diversity, and strategic partnerships becoming essential to survival. In 2023 and 2024, firms faced a contraction in available capital — from $73 billion in 2021 down to $35 billion in 2023 — yet collaborative and manufacturing partnerships have been on the rise. This suggests that dealmaking is evolving, not disappearing. Who Should Purchase and Read This Report This report is essential for: Biotech and pharma execs seeking M&A or licensing opportunities VC/PE investors tracking funding cycles and active biotech targets Strategic planners and BD professionals looking to benchmark activity Consultants, CROs, and CMOs aligning services with market needs Regulatory and policy advisors assessing funding shifts and regional dynamics Strategic Use Cases Identify high-activity players and ideal partners for collaboration or acquisition Benchmark funding rounds and valuations for startups or expanding companies Inform R&D focus by tracking which technologies (e.g., CRISPR, AAV) are attracting deals Support global expansion using regional deal patterns and emerging market trends Strengthen regulatory preparedness by understanding the impact of policy shifts on financing Companion Report Available This report pairs with Kalorama's Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 2024–2030 (4th Edition) — offering disease-area breakdowns of the CGT landscape in oncology, neurology, musculoskeletal, and beyond. Get the Report Download or purchase the report here:Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 (3rd Edition) Explore the companion report:Cell and Gene Therapy Market Dynamics by Disease Type, 2024–2030 (4th Edition) About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide. For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales For media inquiries please contact:Alisa AlvichMarketing
